Across the first phase of the pandemic, AstraZeneca went from being a good example of how pharma can step up in times of need to a warning that no good deed goes unpunished. Now, AstraZeneca has a shot at putting its vaccine woes behind it by carving out a space for a product that may address one of the remaining unmet COVID-19 needs in the West.
AstraZeneca teed up the opportunity last month when it linked its long-acting antibody cocktail to a 77% reduction in the risk of symptomatic coronavirus infection.
